Abivax: +2.5% for the Stock This Morning
French biotech Abivax has gained 2.35% to €97.85 by midday this Tuesday, May 19, 2026. The stock is performing in a well-oriented Parisian market, with the SBF 120 up 0.88% during the session. Over one year, the performance remains exceptional, at over 1700%.
A Limited Technical Rebound After Post-Capital Raise Decline
The stock rebounds after a downward trend that cost nearly 6% over the week. The biotech had surpassed €110 in early May following the buyback of its royalty certificates and a $45 million ADS raise, before falling below €100. The price remains below its 20 and 50-day moving averages, both around €100.7. Conversely, it maintains a 6.7% lead over the 200-day moving average at €91.74, which is nearly at the lower Bollinger band (€91.36). This zone, close to the identified support threshold at €93.50, contained last week's decline. The RSI at 42 remains neutral and the position at the lower end of the Bollinger band (35%) indicates exhaustion of the selling movement. Regarding flows, the net short positions declared accumulate to 2.49% of the capital according to the reviewed declarations, down by 0.32 points over thirty days. Three Anglo-Saxon funds concentrate most of the selling pressure, but this has been easing for a month.
Focus on the First Quarter 2026 Results Scheduled for June 1
The financial calendar is getting busier. The next key event is on June 1 with the announcement of the first quarter 2026 results. This will be followed by the half-year results on September 14 and the third quarter results on December 14. The company presented nine scientific abstracts on obefazimod, its candidate treatment for ulcerative colitis, at the Digestive Disease Week held in Chicago in early May. The capital operations at the beginning of the month (buyback of royalty certificates and issuance of ADS for $45 million) have also simplified the company's financial structure. The one-month volatility is high, at 56.15%, indicating that the stock remains very sensitive to information flow. With more than 50% of the capital held by institutional investors, the next fundamental catalyst will be the quarterly publication on June 1.
